Our data support previous observations, that PDGFRα mutations play no important role in metastasized GISTs. The influence of Imatinib and Sunitinib therapy in metastasized GISTs with wild type genotype and c-kit exon 9 mutations needs further investigation. 
Introduction
Gastrointestinal stromal tumours (GIST) are the most common mesenchymal neoplasms of the gastrointestinal tract with an incidence of approximately 0.65 -1.5 cases per 100'000 inhibitants (1) (2) (3) (4) (5) (6) . The most frequently affected sites are stomach and small intestine, but GISTs may also develop in any other part of the GI tract, peritoneum and retroperitoneum.
The finding, that approximately 95% of these tumours express CD117 (c-kit tyrosine kinase receptor) (7) (8) , has dramatically increased the diagnostic accuracy of these tumours. On a molecular level most GISTs harbour hyperactivating somatic mutations either in c-kit or PDGFR genes, occurring mostly in the juxtamembrane domains or in the extracellular region (9) (10) . This is the rationale for the treatment option with tyrosine kinase inhibitors like Imatinib (Gleevec®, Novartis, Switzerland) or Sunitinib (Sutent®, Pfizer, USA). The localisation of these mutations determines the efficiency of these substances, to inhibit the stimulatory effect of c-kit and PDGFR proteins on cell growth (11) (12) .
In the last few years some unselected population-based studies from various European regions have been published, in which the mutational status of primary GISTs was investigated (2-6).
In one of these studies, the genomic status of metastases was reported (2) , but no correlation to the genomic status of corresponding primary tumour on the one hand and to the response after treatment with Imatinib and Sunitinib on the other hand was given.
The aim of our study was to evaluate the status of c-kit and PDGFR mutations in metastasized GISTs of an unselected population in Central Switzerland, to describe the mutational spectrum of primary and corresponding metastatic tumours. In addition we correlated these results with the response to treatment with tyrosine kinase inhibitors Imatinib and Sunitinib.
Materials and methods

Ethical considerations
This was a retrospective study with no study-driven clinical intervention. No material was sent to external institutions. Approval of the local ethics committee was obtained (reference number EK 915).
Retrieval of cases
The record files of the Institute of Pathology of the Cantonal Hospital Lucerne were searched for all patients with GIST diagnosed in the period from 1995 -2009. The search included all sites of the gastrointestinal tract as well as the intra-abdominal, mesenteric, omental, pelvic and retroperitoneal regions. In addition to GIST the search included all benign and malignant mesenchymal neoplasm as well as tumour-like conditions including fibromatosis, desmoids and inflammatory pseudotumour. The pathology reports and histological slides of patients with metastasized disease were re-evaluated (M.R.) and, in questionable cases, GIST diagnosis was confirmed by CD117 immunohistochemistry (see below).
Since only metastasized tumours were investigated no risk stratification of malignancy or pathological staging of the GIST was performed.
Clinical data including the treatment procedures (e.g. chemotherapy with Imatinib or Sunitinib, radiation, other therapies) after diagnosis of the primary and metastatic tumour, the response to therapy, and the state of disease at the end of the observation period were obtained from the treating oncologists.
Immunohistochemical and molecular analysis
Tissue probes of primary and metastatic tumours were fixed in 4% buffered formalin, Table 1 
Results
Of the 87 GIST (crude incidence rate: 0.97 per 100'000 inhabitants of Central Switzerland per year), diagnosed from 1995 to 2009 in our institution, 13 patients (14.9%) had metastatic disease, which equals a crude incidence rate of 0.14 per 100'000 inhabitants of Central Switzerland per year. All primary and all metastatic tumours showed a strong CD117 expression. In three of the 13 metastatic cases, the metastases were diagnosed at the same time as the primary tumour.
Patients and tumour characteristics are summarized in Table 2 . The patients collective included 8 women (61.5%) and 5 men (38.5%), with a median age of 68 years (range 31 -80) at the first GIST diagnosis. Primary tumours (PT) arose in stomach (6 cases; 46.2%), small intestine (4 cases; 30.8%), and 1 case each in pancreas, gastrocolic ligament, and rectovaginal septum. Metastases were found in the liver (6 cases, 33.3%), peritoneum, not otherwise specified (4 cases, 22.2%), omentum (3 cases, 16.7%), and retroperitoneum, mesenterium, rectovaginal septum, lymph nodes and bone (1 case each, 5.6%). 5 of the 13 patients (38.5%) had metastases in different organs (see Table 2 ). In 2 other patients with peritoneal metastases (patient A and C), tissue samples of 2 different, not otherwise specified peritoneal tumour sites were examined.
Histologically 10 of 13 PT showed a spindle cell type (76.9%), 2 PT a mixed spindle cell / epitheloid type (15.4%), and one tumour of the small intestine an epitheloid type (7.7%).
The median of the greatest diameter of PT was 9.5 cm (range 4 -25 cm). Only 1 PT was less than 5 cm (7.7%), 6 PT ranged between 5 and 10 cm (46.2%), and 5 PT were greater than 10 cm (38.5%). For one PT, confirmed by biopsy, no reliable tumour size was available.
The mitotic count (per 50 high power fields (hpf)) ranged from 1 to 100 with a median of 8.
The highest counts were observed in PT of the stomach (up to 100 mitoses per 50 hpf) and the small intestine (up to 40 mitoses per 50 hpf), whereas the extragastrointestinal PT showed a low mitotic count (range 1 to 6 mitoses per 50 hpf).
Molecular analyses could be performed in all PT and all above described corresponding metastases (see also Table 2 ). In patients with more than one metastatic site, the different metastases of the respective patient showed always the same genetic alterations. In 2 cases with PT in the stomach (patient C and H; 15.4%) no genetic alterations in the c-kit or in the PDGFR- genes could be detected neither in PT nor in metastases. The other 11 cases (84.6%) showed changes in the c-kit gene, but none in the PDGFR- gene. C-kit exon 9 alterations could be detected in 2 PT of the small intestine and in the one PT of the pancreas.
In all 3 cases the same well known duplication of codon 502-503 (p.502_503dup AY) was found in PT as well as in metastatic tumours in heterozygous form. Both PT and metastasis of the GIST of the septum rectovaginale showed a heterozygous exon 13 point mutation (p.K642E). The vast majority of PT (7 patients with PT in stomach, small intestine, and lig. In 1 case (patient A) a dose elevation to 600mg/day was performed after 38 months for another 25 months. In 2 other patients (E and F) the imatinib dosage was increased to 800 mg/day after 20 month for 1 month and after 38 months for 3 months, respectively. The therapy was switched to Sunitinib in 5 patients (37.5 mg in 4 cases, 50 mg in one case, see also Table 2 ) due to tumour progression (3 patients), intolerance (1 patient) or a combination of both (1 patient) during imatinib application. The Sunitinib therapy in 3 of these 5 patients was stopped due to the same reasons (2 patients with intolerance, 1 patient with tumour progression). In patient E, Imatinib therapy was replaced by radiotherapy (30 Gy for 2 weeks). In two patients, Imatinib therapy was terminated without substitution because of tumour progression (patient B) and side effects (patient H), respectively.
In all 3 patients with alterations of the c-kit exon 9 a tumour progression was observed during Imatinib therapy, which was therefore stopped. Whereas 1 of the 2 remaining patients, in which the Imatinib therapy had to be ended due to tumour progression, showed no detectable -9 -genetic alteration, the other one showed more genetic alterations in the metastasis compared to the PT: The heterozygous deletion in exon 11 of the c-kit gene of the PT changed to a homozygous deletion in metastasis and an additional point mutation in exon 13 of the c-kit gene was detected.
Unfortunately, no clinical follow-up data exists for the two cases (patients K and L) that harbour the novel complex genetic alterations in exon 11 of the c-kit gene.
Discussion
The present study is, to our knowledge, the first, which focuses on metastatic GIST in a population-based collective, analysing both the mutational status and response to tyrosine kinase inhibitor therapy.
Our population data with a GIST crude incidence of 0.97 per 100'000 inhabitants per year and a proportion of 14% metastasized GIST is comparable to data reported by other groups (2-6).
Compared to the study of Braconi and colleagues (2) , which provides data of primary metastasized tumours of their whole GIST collective, the mutational status of our collective, included primary and secondary metastasized tumours, shows a slightly higher amount of wild type GIST (15.4% vs. 5%) and a similar proportion of c-kit mutations (84.6% vs. 90%).
In contrast to their study (5%) we could not detect any PDGFR mutation.
Also the site distribution of tumours (46.2% stomach, 30.8% small intestine, 24% other sites) is comparable to the data presented by Braconi et al. A difference could be observed in the histologic type of the tumours: While the vast majority of tumours in the present series showed a spindle cell type (76.9%) and only 15.4% and 7.7% a mixed or epitheloid type, respectively, more epitheloid (26%) and mixed type (31%) GISTs were reported in the metastatic group in their study.
The genetic alterations of the investigated metastatic GIST's are comparable to those, reported in literature for recurrent and metastasized GIST. The most frequently altered exon in the primary tumours of our study group was c-kit exon 11 (54%) with 5 deletions, 1 duplication, and 1 missense point mutation. Other observed genetic alterations occurred in the c-kit exon 9 (23%) and c-kit exon 13 (8%), while 2 PT (15%) showed a c-kit and PDGFR wild type status. Similar results have also been described in previous publications (2, 9, 13-14).
- 11 - The fact that we could not detect any PDGFR mutations in our group of malignant GIST supports the assumption, that GISTs with this genetic alteration are associated with a lower malignant potential and therefore have a better prognosis (10, 14) .
The exon 11 alterations, which mostly occur in gastric GIST (5, 14) , were also mostly detected in our PT of the stomach (4 of 7 cases). In 3 of these 4 cases, for which a clinical follow-up was available, a stable disease or no evidence of disease was observed, which is congruent with published data (12) . No correlation between outcome and type of exon 11 alterations could be seen. So the PT of patient D, who died of disease, had the same heterozygous exon 11 deletion (p.W557_K558) as Patient J, who showed no evidence of disease. Interestingly, both showed a switch to homozygosity in their metastatic tumours, which was described as a prognostically unfavourable factor (15) . In addition the metastasis of patient D harboured a point mutation in exon 13. Previous studies showed, that exon 13 alterations result in poor response to tyrosine kinase inhibitor therapy (16) . This could be responsible for the more aggressive course of the disease of this patient, while receiving Imatinib and Sunitinib without any clinical or radiological response. It remains debatable, whether the genetic changes form PT to metastasis in these 2 cases, in which the here investigated metastatic tissue probes were taken after the start of the drug therapy, were a consequence of the administration of imatinib and/or sunitinib. The other 3 patients with exon 11 alterations, who showed a stable disease or no evidence of disease, initially received Imatinib therapy. In one patient the therapy was stopped after the end of the adjuvant cycle (1 year) with no evidence of residual disease. In another patient a change to Sunitinib was necessary due to liver toxicity.
Exon 9 alterations generally seem to be associated with a worse course of disease. In our study all three observed cases showed the frequent p.502_503AY duplication (12, (17) (18) (19) heterozygously in PT and in metastases. The 2 patients with exon 9 mutations and PT in the small intestine showed a tumour progression under tyrosine kinase inhibitor therapy (Imatinib and Sunitinib) and died of disease. One of these two patients (A) showed a tumour progression despite a dosage elevation of imatinib up to 600 mg/day. The third patient with exon 9 alteration, whose PT was located in the pancreas, shows stable disease under Sunitinib treatment after Imatinib therapy was stopped due to tumour progression and side effects.
One of the two patients with wild type GIST was diagnosed only 6 month before the end of our observation period, so no reliable follow-up data is available. The other wild type patient died of disease, showing a rapid tumour progression during tyrosine kinase inhibitor treatment (Imatinib, Sunitinib). This poor response of wild type GIST patients was also repeatedly reported in literature (9, (11) (12) .
In two patients (K and L) we detected novel exon 11 alterations so far not described: A 14 amino acids deletion (p.E554_N567) in case K with heterozygosity in both PT and metastasis and a 12 amino acids duplication (p.P577_R588) in case L, being heterozygous in PT and homozygous in the metastasis. Unfortunately, no clinical follow-up was available.
Until now only a few cases of GIST in the rectovaginal septum have been described in the English literature (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) . In all these reports, similarly to our case, this localization seems to be associated with a favourable prognosis. In the few cases with reported genotyping (24) (25) , no c-kit exon 13 alteration -like in our case -was described.
Taken together, our study, which is based on a population-based collective of metastatic GIST, confirms the observations of other researchers: GISTs with a malignant behaviour are mostly associated with genetic alterations in exons 9 and 11 of the c-kit gene or harbour wildtype c-kit. PDGFR alterations on the other hand only rarely result in metastatic disease.
In here described setting of a population-based observational study with a small number of cases with different, not standardized treatment modalities, it remains difficult, to draw certain conclusions for a possible relation between the genetic alterations of c-kit and PDGFR in PT and metastases, respectively, and the response to tyrosine kinase inhibitor therapy. In tendency, our observations support the results of previous studies, in that GISTs with a wild type genotype or a c-kit exon 9 alteration in primary tumour or a secondary mutation in metastasis show a worse response to Imatinib or Sunitinib treatment than other c-kit alterations. But, especially in patients with exon 9 mutations and treatment with elevated doses of imatinib according to the results of the MetaGIST group (30) , further studies with a larger number of patients with metastasized GIST are needed to confirm these findings.
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